Alpha 2.0
Login Register
» Authors » Tienan Yi

Tienan Yi

Explore the profile of Tienan Yi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 25
Citations 229
Followers 0
Related Specialties
Oncology
General Medicine
Pulmonary Medicine
Top 10 Co-Authors
Yueyin Pan
Shundong Cang
Aimin Zang
Ying Cheng
Jian Fang
Gongyan Chen
Jiuwei Cui
Yun Fan
Dongqing Lv
Jianhua Shi
Published In
Zhongguo Fei Ai Za Zhi
Cancer Commun (Lond)
Lung Cancer
J Clin Oncol
J Thorac Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors
Zhao M, Hu X, Zhuang P, Zeng A, Yu Y, Chen Z, et al.
J Bone Oncol . 2025 Feb; 51:100661. PMID: 39995685
Introduction: Denosumab (Xgeva®) is a standard treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases (BM). This trial was designed to assess the equivalence of LY01011...
2.
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
Shi Y, Guo Y, Li X, Wu L, Chen Z, Yang S, et al.
Lancet Respir Med . 2025 Feb; PMID: 39914443
Background: This study aimed to compare the efficacy and safety of rezivertinib (BPI-7711) and gefitinib as first-line therapies in patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (NSCLC)....
3.
Telpegfilgrastim for chemotherapy-induced neutropenia in breast cancer: A multicenter, randomized, phase 3 study
Shi Y, Zhang Q, Wang J, Ouyang Z, Yi T, Mei J, et al.
Chin Med J (Engl) . 2025 Jan; 138(4):496-498. PMID: 39820410
No abstract available.
4.
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer
Chen Z, Chen J, Huang D, Zhang W, Wu L, Yi T, et al.
Signal Transduct Target Ther . 2025 Jan; 10(1):28. PMID: 39800716
This is a randomized, double-blind, placebo-controlled phase 3 clinical trial (ClinicalTrials.gov, NCT04878016) conducted in 54 hospitals in China. Adults who were histologically diagnosed and never treated for extensive-stage small cell...
5.
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer
Jiang Z, Ouyang Q, Sun T, Zhang Q, Teng Y, Cui J, et al.
Future Oncol . 2024 Dec; 21(4):421-429. PMID: 39628303
No abstract available.
6.
Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT
Zhou H, Zhao Y, Zhang M, Yao J, Leng S, Li X, et al.
J Clin Oncol . 2024 Dec; 43(9):1123-1136. PMID: 39621965
Purpose: Mixed formulation of fosrolapitant and palonosetron (PALO), HR20013, is a novel fixed-dose intravenous antiemetic combination that could simultaneously antagonize neurokinin-1 and 5-hydroxytryptamine-3 receptors. This study was designed to evaluate...
7.
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial
Cheng Y, Zhang W, Wu L, Zhou C, Wang D, Xia B, et al.
JAMA Oncol . 2024 Nov; 11(1):16-25. PMID: 39541202
Importance: Patients with extensive-stage small cell lung cancer (ES-SCLC) have poor prognoses and unmet medical needs. Objective: To evaluate the efficacy and safety of toripalimab plus etoposide and platinum-based chemotherapy...
8.
Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial
Lu S, Zhang Y, Zhang G, Zhou J, Cang S, Cheng Y, et al.
Lung Cancer . 2024 Aug; 195:107901. PMID: 39089004
Background: In the initial analysis of a pivotal phase 2 single-arm study (NCT03861156), befotertinib (D-0316) showed clinical benefit with a manageable safety profile in pretreated patients with EGFR T790M mutated...
9.
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial
Cheng Y, Chen J, Zhang W, Xie C, Hu Q, Zhou N, et al.
Nat Med . 2024 Jul; 30(10):2967-2976. PMID: 38992123
Immunochemotherapy is the first-line standard for extensive-stage small-cell lung cancer (ES-SCLC). Combining the regimen with anti-angiogenesis may improve efficacy. ETER701 was a multicenter, double-blind, randomized, placebo-controlled phase 3 trial that...
10.
Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: a multicenter, randomized, double-blind, placebo-controlled, phase II study
Qin S, Wang Y, Yao J, Liu Y, Yi T, Pan Y, et al.
Ther Adv Med Oncol . 2024 Jun; 16:17588359241260985. PMID: 38882443
Background: Chemotherapy-induced thrombocytopenia (CIT) increases the risk of bleeding, necessitates chemotherapy dose reductions and delays, and negatively impacts prognosis. Objectives: This study aimed to evaluate the efficacy and safety of...